Single User
£5100
PDF
148 pages

PD-L1 Overexpression In Solid Tumours Forecast In 18 Major Markets 2017-2027


PD-1 is a T-cell immune checkpoint that is involved in the dampening of autoimmunity in the peripheral effector phase of T-cell activation. This leads to a ‘tolerance’ of cells expressing PD-L1 (programmed death ligand-1). PD-L1 is expressed normally on a number of different cell types including; placenta, vascular endothelium, pancreatic islet cells, muscle cells, hepatocytes, epithelium, mesenchymal stem cells, B-cells, T-cells, dendritic cells, macrophages and mast cells.

This report provides the current prevalent population for PDL-1 over-expression in cancer populations across 18 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Russia, Turkey, Saudi Arabia, Japan, China, Argentina, Brazil, Mexico, India, South Africa and Australia) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main cancers with PDL-1 over-expression have been quantified and presented alongside the overall prevalence figures.

PDL-1 over-expression is most often associated with the following cancers:

  • Bladder
  • Breast
  • Colorectal Cancer (CRC)
  • Hodgkin’s Lymphoma
  • Kidney
  • Liver
  • NSCLC
  • Melanoma
  • Oesophageal
  • Pancreatic
  • Prostate
  • Stomach

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
  • Able to quantify patient populations in global PDL-1 over-expression market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the PDL-1 over-expression by cancer type and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact of the mutation on the prevalent population for specific cancer types.
  • Gain an understanding of the specific markets that have the largest number of PDL-1 over-expression patients.
Table of Contents
  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key Cancers associated with the condition
  • Methodology for quantification of patient numbers
  • Top-line Prevalence for PD-L1 over-expression in Cancer populations
  • PD-L1 over-expression by type of cancer
  • Abbreviations used in the report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix
List of Tables
  • PD1/PD-L1 checkpoint inhibitors currently licensed for use
  • Prevalence of PDL-1 over-expression, total (000s)
  • Prevalence of PDL-1 over-expression, males (000s)
  • Prevalence of PDL-1 over-expression, females (000s)
  • PD-L1 expression by cancer type, males (000s)
  • PD-L1 expression by cancer type, females (000s)
  • Abbreviations and Acronyms used in the report
  • USA Incidence of breast cancer by 5-yr age cohort, total (000s)
  • USA Incidence of ovarian cancer by 5-yr age cohort, females (000s)
  • USA Incidence of prostate cancer by 5-yr age cohort, males (000s)
  • USA Incidence of pancreatic cancer by 5-yr age cohort, total (000s)
  • USA Incidence of CRC cancer by 5-yr age cohort, total (000s)
  • USA Incidence of stomach cancer by 5-yr age cohort, total (000s)
  • Canada Incidence of breast cancer by 5-yr age cohort, total (000s)
  • Canada Incidence of ovarian cancer by 5-yr age cohort, females (000s)
  • Canada Incidence of prostate cancer by 5-yr age cohort, males (000s)
  • Canada Incidence of pancreatic cancer by 5-yr age cohort, total (000s)
  • Canada Incidence of CRC cancer by 5-yr age cohort, total (000s)
  • Canada Incidence of stomach cancer by 5-yr age cohort, total (000s)
  • France Incidence of breast cancer by 5-yr age cohort, total (000s)
  • France Incidence of ovarian cancer by 5-yr age cohort, females (000s)
  • France Incidence of prostate cancer by 5-yr age cohort, males (000s)
  • France Incidence of pancreatic cancer by 5-yr age cohort, total (000s)
  • France Incidence of CRC cancer by 5-yr age cohort, total (000s)
  • France Incidence of stomach cancer by 5-yr age cohort, total (000s)
  • Germany Incidence of breast cancer by 5-yr age cohort, total (000s)
  • Germany Incidence of ovarian cancer by 5-yr age cohort, females (000s)
  • Germany Incidence of prostate cancer by 5-yr age cohort, males (000s)
  • Germany Incidence of pancreatic cancer by 5-yr age cohort, total (000s)
  • Germany Incidence of CRC cancer by 5-yr age cohort, total (000s)
  • Germany Incidence of stomach cancer by 5-yr age cohort, total (000s)
  • Italy Incidence of breast cancer by 5-yr age cohort, total (000s)
  • Italy Incidence of ovarian cancer by 5-yr age cohort, females (000s)
  • Italy Incidence of prostate cancer by 5-yr age cohort, males (000s)
  • Italy Incidence of pancreatic cancer by 5-yr age cohort, total (000s)
  • Italy Incidence of CRC cancer by 5-yr age cohort, total (000s)
  • Italy Incidence of stomach cancer by 5-yr age cohort, total (000s)
  • Spain Incidence of breast cancer by 5-yr age cohort, total (000s)
  • Spain Incidence of ovarian cancer by 5-yr age cohort, females (000s)
  • Spain Incidence of prostate cancer by 5-yr age cohort, males (000s)
  • Spain Incidence of pancreatic cancer by 5-yr age cohort, total (000s)
  • Spain Incidence of CRC cancer by 5-yr age cohort, total (000s)
  • Spain Incidence of stomach cancer by 5-yr age cohort, total (000s)
  • UK Incidence of breast cancer by 5-yr age cohort, total (000s)
  • UK Incidence of ovarian cancer by 5-yr age cohort, females (000s)
  • UK Incidence of prostate cancer by 5-yr age cohort, males (000s)
  • UK Incidence of pancreatic cancer by 5-yr age cohort, total (000s)
  • UK Incidence of CRC cancer by 5-yr age cohort, total (000s)
  • UK Incidence of stomach cancer by 5-yr age cohort, total (000s)
  • Russia Incidence of breast cancer by 5-yr age cohort, total (000s)
  • Russia Incidence of ovarian cancer by 5-yr age cohort, females (000s)
  • Russia Incidence of prostate cancer by 5-yr age cohort, males (000s)
  • Russia Incidence of pancreatic cancer by 5-yr age cohort, total (000s)
  • Russia Incidence of CRC cancer by 5-yr age cohort, total (000s)
  • Russia Incidence of stomach cancer by 5-yr age cohort, total (000s)
  • Turkey Incidence of breast cancer by 5-yr age cohort, total (000s)
  • Turkey Incidence of ovarian cancer by 5-yr age cohort, females (000s)
  • Turkey Incidence of prostate cancer by 5-yr age cohort, males (000s)
  • Turkey Incidence of pancreatic cancer by 5-yr age cohort, total (000s)
  • Turkey Incidence of CRC cancer by 5-yr age cohort, total (000s)
  • Turkey Incidence of stomach cancer by 5-yr age cohort, total (000s)
  • Saudi Arabia Incidence of breast cancer by 5-yr age cohort, total (000s)
  • Saudi Arabia Incidence of ovarian cancer by 5-yr age cohort, females (000s)
  • Saudi Arabia Incidence of prostate cancer by 5-yr age cohort, males (000s)
  • Saudi Arabia Incidence of pancreatic cancer by 5-yr age cohort, total (000s)
  • Saudi Arabia Incidence of CRC cancer by 5-yr age cohort, total (000s)
  • Saudi Arabia Incidence of stomach cancer by 5-yr age cohort, total (000s)
  • Brazil Incidence of breast cancer by 5-yr age cohort, total (000s)
  • Brazil Incidence of ovarian cancer by 5-yr age cohort, females (000s)
  • Brazil Incidence of prostate cancer by 5-yr age cohort, males (000s)
  • Brazil Incidence of pancreatic cancer by 5-yr age cohort, total (000s)
  • Brazil Incidence of CRC cancer by 5-yr age cohort, total (000s)
  • Brazil Incidence of stomach cancer by 5-yr age cohort, total (000s)
  • Mexico Incidence of breast cancer by 5-yr age cohort, total (000s)
  • Mexico Incidence of ovarian cancer by 5-yr age cohort, females (000s)
  • Mexico Incidence of prostate cancer by 5-yr age cohort, males (000s)
  • Mexico Incidence of pancreatic cancer by 5-yr age cohort, total (000s)
  • Mexico Incidence of CRC cancer by 5-yr age cohort, total (000s)
  • Mexico Incidence of stomach cancer by 5-yr age cohort, total (000s)
  • Argentina Incidence of breast cancer by 5-yr age cohort, total (000s)
  • Argentina Incidence of ovarian cancer by 5-yr age cohort, females (000s)
  • Argentina Incidence of prostate cancer by 5-yr age cohort, males (000s)
  • Argentina Incidence of pancreatic cancer by 5-yr age cohort, total (000s)
  • Argentina Incidence of CRC cancer by 5-yr age cohort, total (000s)
  • Argentina Incidence of stomach cancer by 5-yr age cohort, total (000s)
  • Japan Incidence of breast cancer by 5-yr age cohort, total (000s)
  • Japan Incidence of ovarian cancer by 5-yr age cohort, females (000s)
  • Japan Incidence of prostate cancer by 5-yr age cohort, males (000s)
  • Japan Incidence of pancreatic cancer by 5-yr age cohort, total (000s)
  • Japan Incidence of CRC cancer by 5-yr age cohort, total (000s)
  • Japan Incidence of stomach cancer by 5-yr age cohort, total (000s)
  • China Incidence of breast cancer by 5-yr age cohort, total (000s)
  • China Incidence of ovarian cancer by 5-yr age cohort, females (000s)
  • China Incidence of prostate cancer by 5-yr age cohort, males (000s)
  • China Incidence of pancreatic cancer by 5-yr age cohort, total (000s)
  • China Incidence of CRC cancer by 5-yr age cohort, total (000s)
  • China Incidence of stomach cancer by 5-yr age cohort, total (000s)
  • India Incidence of breast cancer by 5-yr age cohort, total (000s)
  • India Incidence of ovarian cancer by 5-yr age cohort, females (000s)
  • India Incidence of prostate cancer by 5-yr age cohort, males (000s)
  • India Incidence of pancreatic cancer by 5-yr age cohort, total (000s)
  • India Incidence of CRC cancer by 5-yr age cohort, total (000s)
  • India Incidence of stomach cancer by 5-yr age cohort, total (000s)
  • Australia Incidence of breast cancer by 5-yr age cohort, total (000s)
  • Australia Incidence of ovarian cancer by 5-yr age cohort, females (000s)
  • Australia Incidence of prostate cancer by 5-yr age cohort, males (000s)
  • Australia Incidence of pancreatic cancer by 5-yr age cohort, total (000s)
  • Australia Incidence of CRC cancer by 5-yr age cohort, total (000s)
  • Australia Incidence of stomach cancer by 5-yr age cohort, total (000s)
  • South Africa Incidence of breast cancer by 5-yr age cohort, total (000s)
  • South Africa Incidence of ovarian cancer by 5-yr age cohort, females (000s)
  • South Africa Incidence of prostate cancer by 5-yr age cohort, males (000s)
  • South Africa Incidence of pancreatic cancer by 5-yr age cohort, total (000s)
  • South Africa Incidence of CRC cancer by 5-yr age cohort, total (000s)
  • South Africa Incidence of stomach cancer by 5-yr age cohort, total (000s)
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Russian Federation, Saudi Arabia, South Africa, Spain, Turkey, United Kingdom, United States of America